Navigating Drug Trials and Cancer Research with Professor Dario Neri (#01)
Episode Summary: Dario Neri on the pursuit to cure cancer
Dario Neri is the co-founder, CEO, and CSO of Philogen, with an extensive background in pharmaceutical research and development. The conversation explores his journey in academia, including working under Nobel Prize winners, and transitions into the complexities of publishing medical research and why fields like COVID-19 often generate conflicting information.
Expect to learn about the challenges of bringing a drug to market, including the rigorous phases of drug trials, the pressures from shareholders to expedite approvals, and how varying global regulations shape the pharmaceutical landscape. Dario also shares his views on the negative reputation of the pharma industry, the dynamics between cancer treatment companies, and whether they act as competitors or allies, along with much more…
About Dario Neri: Innovator in Biopharmaceuticals
Dario Neri is the Co-founder, Chief Executive Officer, and Chief Scientific Officer of Philogen, a company at the forefront of developing innovative cancer treatments. He earned his Ph.D. in Chemistry from ETH Zurich under the mentorship of Professor Kurt Wüthrich, the 2002 Nobel Prize winner in Chemistry, and received the prestigious Silver Medal of ETH for his dissertation.
Dario further honed his expertise at the Cambridge Centre of Protein Engineering under Sir Gregory Winter, the 2018 Nobel Prize winner in Chemistry. He returned to ETH Zurich in 1996, eventually becoming a Full Professor of Biomacromolecules in 1999. In 2020, Dario joined Philogen full-time, while still retaining his professorial title at ETH Zurich.
With over 400 publications in international scientific journals and a career marked by numerous accolades, Dario Neri has significantly contributed to the fields of medicinal chemistry and biotechnology. His leadership at Philogen exemplifies the bridge between groundbreaking research and real-world medical solutions.
Transcript
Coming Soon…
